Due Diligence (2)

Challenge: A leading NK cell research group had developed a novel process for manufacturing NK cells with highly differentiated properties. The technology had been licensed to a start-up company that...

Challenge: A late pre-clinical biotech company engaged in the development of antibody drug conjugates (ADCs) targeting GPCRs for treatment of solid tumors asked Alacrita to conduct an internal due...

Challenge: Our client was a US-based venture capital fund, with whom we have a long-standing retainer agreement to provide specialized due diligence support for their fund investment decisions. In...

Challenge: An east coast biotechnology company had reached non-binding terms with an overseas company for development and commercialization rights to a novel anti-cancer product with a...

Challenge: A well-capitalized US biotechnology company was considering entry into the CAR-T space through a license and research collaboration with a leading US university with a distinguished and...

Challenge: A mid-sized Japanese pharmaceutical company had made the strategic decision to expand their pipeline and geographical footprint by securing global development and commercialization rights...

Challenge: A private equity investor was considering a transaction involving a speciality pharma company dedicated to pediatric medicines. The target company had successfully launched a major product...

Challenge: A Chinese biotech company was evaluating a potential in-license product, a first-in-class agent for the treatment of ataxia and tremors in patients with Spinocerebellar Ataxia (SCA). The...

Challenge: An established Alacrita client building a business in the inhaled therapeutics sector asked us to carry out a technical and commercial due diligence of two development stage companies...

Challenge: A contract development and manufacturing organization (CDMO) was in negotiations to acquire two manufacturing sites from other companies. Under normal circumstances, the client would have...

Challenge: For a mid-size European pharma company thinking of entering a new therapeutic area, we conducted ‘Triage’ level due diligence which focused only on publicly available information for three...

Challenge: A European investment trust was considering an investment in a Phase 3 gene therapy opportunity targeting a niche oncology indication. Owing to the circumstances of the deal, they had less...